Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results
Source: BioPharma Dive - Latest News
An amylin-targeting medicine at the center of the companies’ multibillion-dollar alliance spurred less weight loss than investors had hoped, leading some analysts to question its ability to stand out.